Several Wall Street analysts have recently upgraded their ratings for a handful of publicly traded companies, indicating a positive shift in their outlook for these businesses. These upgrades reflect the analysts’ belief that these companies are poised for growth or improvement in the near future.
Gordon Haskett analyst Eric Cohen upgraded the rating for Ollie’s Bargain Outlet Holdings Inc (OLLI) from ‘Accumulate’ to ‘Buy’. This move suggests that Cohen believes Ollie’s is a good investment opportunity. He also increased the price target for the stock from $105 to $107, suggesting he sees potential for the stock to rise further. Ollie’s shares closed at $98.89 on Friday.
Meanwhile, JP Morgan analyst Christopher Horvers upgraded the rating for BJ’s Wholesale Club Holdings Inc (BJ) from ‘Underweight’ to ‘Neutral’. This upgrade signifies that Horvers believes BJ’s is no longer a poor investment, although he is not recommending it as a strong buy. He also raised the price target from $76 to $78, suggesting he sees some upside potential for the stock. BJ’s shares closed at $82.77 on Friday.
Argus Research analyst Gary Hovis upgraded the rating for Xcel Energy Inc (XEL) from ‘Hold’ to ‘Buy’. Hovis now sees Xcel Energy as a good investment opportunity, potentially performing better than the market. He also set a price target of $68, suggesting the stock could rise to that level in the future. Xcel Energy shares closed at $60.12 on Friday.
In another move, Wells Fargo analyst James Feldman upgraded Camden Property Trust (CPT) from ‘Underweight’ to ‘Equal-Weight’. Feldman no longer considers Camden Property Trust a poor investment, but also does not view it as a strong buy. He also boosted the price target from $104 to $127, hinting at a potential rise in the stock price. Camden Prop Trust shares closed at $122.60 on Friday.
Finally, Wolfe Research analyst Andy Chen upgraded the rating for Kymera Therapeutics Inc (KYMR) from ‘Peer Perform’ to ‘Outperform’. Chen now believes Kymera Therapeutics is positioned to outperform its peers. He also announced a price target of $65, reflecting his expectation that the stock will rise to that level. Kymera Therapeutics shares closed at $47.78 on Friday.
These analyst upgrades offer insights into the current market sentiment and potential investment opportunities. Investors may wish to consider these upgrades when making investment decisions, but it is always recommended to conduct thorough research and seek advice from financial professionals before making any investment choices.
